P
P

Pfizer


News

British Business - July 28

July 28 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - The largest investor in WM Morrison Supermarkets Plc MRW.L , Silchester International Investors, said it is 'not inclined' to support a 6.3 billion pounds ($8.74
A
P
T

Antibodies from Sinovac's 19 shot fade after about 6 months, booster helps - study

(Updates with study details, comment from Philippine health official, background) BEIJING, July 27 (Reuters) - Antibodies triggered by Sinovac Biotech's SVA.O COVID-19 vaccine declined below a key threshold from around six months after a second dose for most recipients, although a third shot had a strong booster effect, according to a lab study. Ch
P

S.Korea begins 19 vaccination for chip, electronics workers

By Sangmi Cha SEOUL, July 27 (Reuters) - South Korea on Tuesday launched COVID-19 vaccinations for workers at key computer chip and electronic businesses to minimise disruptions in the global supply chain amid struggles to keep up with its inoculation schedule. Major tech companies including Samsung Electronics Co Ltd 005930.KS , Samsung Display Co
P

S.Korea says Moderna reports 'production issue' as vaccination widens to 50s

(Updates with Moderna production issue) By Sangmi Cha and Hyonhee Shin SEOUL, July 26 (Reuters) - South Korea said on Monday it has been informed by Moderna MRNA.O of an unspecified production issue involving its COVID-19 vaccine, as the country expands its inoculation campaign for people aged 55-59 amid a fourth wave of infections. It was not imme
P

Aspen to start J&J 19 vaccine supplies to South Africa from Monday

JOHANNESBURG, July 26 (Reuters) - South Africa's Aspen Pharmacare APNJ.J will supply the first batch of Johnson & Johnson JNJ.N COVID-19 vaccine to the country from July 26, the drugmaker said on Monday. It will be the first set of vaccines to be manufactured in the country from active pharmaceutical ingredients (API) - substances used to make the
P

Wall Street Journal - July 26

July 26 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Immunity against the coronavirus is waning in people who were fully vaccinated with the shot made by BioNTech SE 22UAy.DE and Pfizer Inc PFE.N in January because of the rapidly spreading D
P

Wall St Week Ahead-Big tech companies retake market reins with earnings on tap

By Lewis Krauskopf NEW YORK, July 23 (Reuters) - The rally on Wall Street faces a fresh test next week with a flood of earnings reports from major U.S. companies, including the tech and internet behemoths that have recently retaken leadership of the market. More than one third of the S&P 500 is set to report quarterly results next week, headlined b
A
A
F
G
M
P
T
V
U

Wall St Week Ahead-Big tech companies retake market reins with earnings on tap

By Lewis Krauskopf NEW YORK, July 23 (Reuters) - The rally on Wall Street faces a fresh test next week with a flood of earnings reports from major U.S. companies, including the tech and internet behemoths that have recently retaken leadership of the market. More than one third of the S&P 500 is set to report quarterly results next week, headlined b
A
A
F
G
M
P
T
V
U

U.S. top diplomat Blinken to visit India, Kuwait

WASHINGTON, July 23 (Reuters) - U.S. Secretary of State Antony Blinken will travel to India next week, the State Department said on Friday, in the top U.S. diplomat's first visit to the world's largest democracy and an important U.S. ally in Asia. Blinken will also visit Kuwait and meet senior officials there at the end of the July 26-29 trip. The
P

CDC guidance on masking unchanged as Delta variant sweeps U.S. - Walenksy

By Carl O'Donnell and Jeff Mason July 22 (Reuters) - The U.S. Centers for Disease Control and Prevention has not revised its masking guidance, even as the infectious Delta variant of COVID-19 continues to sweep the United States, driving up case counts, CDC director Rochelle Walensky said during a Thursday press call. Walensky declined to say if th
P

Australian PM apologises for 19 vaccine delays as cases spike

* NSW reports 124 new cases, from 110 a day earlier * Victoria reports 26 cases, up from 22 * More than half Australia's 25 mln population under lockdown By Renju Jose and Byron Kaye SYDNEY, July 22 (Reuters) - Australia's prime minister apologised for a sluggish COVID-19 vaccination programme on Thursday, while the country's most populous state re
A
P
Q

Delta COVID variant now dominant strain worldwide; U.S. deaths surge -officials

By Carl O'Donnell and Jeff Mason July 16 (Reuters) - The Delta variant of COVID-19 is now the dominant strain worldwide, accompanied by a surge of deaths around the United States almost entirely among unvaccinated people, U.S. officials said Friday. U.S. cases of COVID-19 are up 70% over the previous week and deaths are up 26%, with outbreaks occur
P

Malaysia to allow commercial sale of 19 vaccines

By Rozanna Latiff and Joseph Sipalan KUALA LUMPUR, July 16 (Reuters) - Malaysia will soon allow the commercial sale of COVID-19 vaccines manufactured by Chinese firms Sinopharm 1099.HK and Sinovac SVA.O , the science minister said on Friday, as authorities try to ramp up inoculation rates amid surging cases. Malaysia has one of the region's highest
A
P

Thai hospital tycoon sticks to guns on vaccine claims

By Chayut Setboonsarng BANGKOK, July 16 (Reuters) - Thailand’s Thonburi Healthcare Group Pcl (THG) THG.BK doubled down on its outspoken chairman's claim to be buying Pfizer-BioNTech vaccines on Friday, helping its share price rise despite denials by both drugmakers. Dr. Boon Vanasin's claim that his group, a more than $800 million private medicin
A
P

Pfizer says only in talks with government bodies in Thailand

July 15 (Reuters) - Pfizer PFE.N on Thursday said it was only in talks with the Thai government, after a Thai hospital group said it was signing a deal for 20 million doses of COVID-19 vaccines. "We are in ongoing discussions with Thailand’s Department of Disease Control, Ministry of Public Health only," Pfizer said in a statement after the chair
P

Pfizer, BioNTech deny talks with Thai Thonburi Healthcare on vaccines

(Updates with denial from Pfizer) By Chayut Setboonsarng BANGKOK, July 15 (Reuters) - Pfizer PFE.N and Germany's BioNTech 22UAy.DE denied on Thursday that they were in talks with Thailand's Thonburi Healthcare Group Pcl THG.BK for a deal to import 20 million doses of the coronavirus vaccine to the Southeast Asian country. The chief of Thonburi Heal
A
P

Grappling with 'worst-case scenario', Indonesia faces more 19 pain

* Minister says Indonesia prepared if cases top 60,000 per day * Government assessing how much longer mobility curbs to run * Union estimates over 10% of manufacturing workers infected By Gayatri Suroyo and Stanley Widianto July 15 (Reuters) - Indonesia is already grappling with a "worst-case scenario" COVID-19 situation, a senior minister said on
P

EU regulator weighing mixing 19 vaccines, booster doses

* Says 'not in position' to advise on use of different doses * Says countries may adapt strategies based on available evidence * Finds no 'clear' link between Moderna shot, new blood condition * EC says it follows science, but needs to be prepared By Pushkala Aripaka July 14 (Reuters) - Europe's drug regulator on Wednesday refrained from making any
A
P

Vietnam says Pfizer to provide 20 mln vaccine doses, consider tech transfer

HANOI, July 14 (Reuters) - Vietnam on Wednesday said U.S. vaccine maker Pfizer PFE.N would provide an additional 20 million doses of its COVID-19 mRNA shot, as the country tries to shore up supplies at a time of record number of new infections. The additional Pfizer-BioNTech 22UAy.DE vaccines would be used for 12-18 year olds, its health ministry s
A
P

Thai state drugmaker sues critic of its vaccine procurement

BANGKOK, July 14 (Reuters) - Thailand's state drugmaker on Wednesday said it had initiated a defamation suit against the prominent chairman of a private hospital operator over his criticism of its procurement of Moderna MRNA.O COVID-19 vaccines. The Government Pharmaceutical Organization (GPO) suit accuses Boon Vanasin of providing false informatio
A
P



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.